Exencial Wealth Advisors LLC Has $2.60 Million Position in Stryker Corporation $SYK

Exencial Wealth Advisors LLC cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 2.5% during the second quarter, Holdings Channel reports. The fund owned 6,575 shares of the medical technology company’s stock after selling 172 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Stryker were worth $2,601,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Stryker by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after acquiring an additional 361,136 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after acquiring an additional 1,021,496 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after acquiring an additional 261,058 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Stryker by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock worth $776,871,000 after acquiring an additional 83,954 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Stryker by 1.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock worth $750,223,000 after acquiring an additional 30,329 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on SYK shares. UBS Group set a $408.00 target price on Stryker in a report on Monday, October 13th. Barclays boosted their price target on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday. Needham & Company LLC boosted their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Truist Financial reduced their price target on Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a research note on Wednesday, October 15th. Finally, Redburn Partners set a $420.00 price target on Stryker in a research note on Thursday, September 18th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $432.24.

Stryker Stock Performance

SYK opened at $387.84 on Thursday. The business has a fifty day simple moving average of $379.74 and a 200 day simple moving average of $379.16. The company has a market capitalization of $148.27 billion, a PE ratio of 51.37, a price-to-earnings-growth ratio of 2.74 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is presently 44.50%.

Insiders Place Their Bets

In other news, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.